By Kate Hammeke, VP of Market Research, Industry Standard Research (ISR) @ISRreports
For the past six years, Industry Standard Research has asked oral dose outsourcers about the proportions of their projects that are simple, neither simple nor complex, and complex. Considering the formulation challenges and solubility issues that can come with more complex molecules, I anticipated there would be an uptick in the proportions of complex oral dose projects over time. Data from ISR’s research on oral dose manufacturing suggests my hypothesis was wrong. At least for now.
Read more at bioprocessonline.com.
